安硕

[摘要] 目的 探讨功能性消化不良患者应用莫沙必利治疗的临床疗效与安全性。方法 该研究方便选取该院于2015年8月—2016年8月收治的 70例功能性消化不良患者，根据应用不同的药物治疗均分为观察组与对照组各35例。对照组给予多潘立酮片进行治疗，观察组给予莫沙必利进行治疗。记录并比较两组功能性消化不良患者的治疗有效率、胃排空率与不良反应发生率。 结果 观察组功能性消化不良患者的治疗总有效率（94.29%）明显高于对照组功能性消化不良患者的治疗总有效率（77.14%），经比较差异有统计学意义（P<0.05）；觀察组功能性消化不良的胃排空率（75.57±19.58）明显高于对照组功能性消化不良的胃排空率（59.38±18.66），经比较差异有统计学意义（P<0.05）；观察组功能性消化不良患者的不良反应发生率（14.29%）与对照组功能性消化不良患者的不良反应发生率（20.00%）比较差异无统计学意义（P>0.05）。结论 莫沙必利对功能性消化不良患者的治疗效果较显著，且明显提高了患者的胃排空率，具有较高的安全性，可再临床上广泛的应用与推广。

[关键词] 莫沙必利；功能性消化不良；多番立酮片；安全性

[中图分类号] R570.5 [文献标识码] A [文章编号] 1674-0742（2017）05（b）-0127-03

[Abstract] Objective To study the clinical curative effect and safety of mosapride in treatment of functional dyspepsia. Methods 70 cases of patients with functional dyspepsia admitted and treated in our hospital from August 2015 to August 2016 were convenient selected and divided into two groups with 35 cases in each according to different drug treatment， the control group were treated with domperidone tablets， while the observation group were treated with mosapride， and the treatment effective rate， gastric evacuation rate and incidence rate of adverse reactions were compared between the two groups. Results The total effective rate of patients in the observation group was obviously higher than that in the control group（94.29% vs 77.14%）， and the difference was obvious（P<0.05）， and the gastric evacuation rate in the observation group was obviously higher than that in the control group[（75.57±19.58） vs （59.38±18.66）]， and the difference was obvious（P<0.05）， and there was no obvious difference in the incidence rate of adverse reactions between the observation group and the control group，（14.29% vs 20.00%）（P>0.05）. Conclusion The effect of mosapride in treatment of functional dyspepsia patients is obvious， which can obviously improve the gastric evacuation rate of patients with higher safety， and it can be widely applied and promoted in clinic.

[Key words] Mosapride； Functional dyspepsia； Domperidone tablets； Safety

功能性消化不良是一种临床上常见的消化道系统疾病，临床表现多为恶心呕吐、上腹部伴有烧灼感、食欲减退及餐后腹胀等症状[1]。促胃肠动力药物是治疗功能性消化不良最广泛使用的药物，莫沙必利是一种5-HT4受体激动剂，可对患者的上消化道运动产生刺激作用以改善患者的胃动力。该研究方便选取该院于2015年8月—2016年8月收治的 70例功能性消化不良患者，对功能性消化不良患者应用莫沙必利治疗的临床疗效与安全性进行探讨，现报道如下。

1 资料与方法

1.1 一般资料

该研究方便选取该院收治的70例功能性消化不良患者，根据应用不同的药物治疗均分为观察组与对照组各35例。……